BridgeBio Oncology Therapeutics, Inc.
BBOT
$11.07
-$0.28-2.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 14.13M | 2.66M | 2.50M | 1.78M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 49.18M | 30.09M | 23.14M | 19.66M | |
| Operating Income | -49.18M | -30.09M | -23.14M | -19.66M | |
| Income Before Tax | -44.76M | -28.44M | -22.06M | -17.32M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -44.76M | -28.44M | -22.06M | -17.32M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -44.76M | -28.44M | -22.06M | -17.32M | |
| EBIT | -49.18M | -30.09M | -23.14M | -19.66M | |
| EBITDA | -49.11M | -30.02M | -23.08M | -19.61M | |
| EPS Basic | -1.03 | -50.36 | -54.23 | -1.56K | |
| Normalized Basic EPS | -0.64 | -31.48 | -33.89 | -976.36 | |
| EPS Diluted | -1.03 | -50.36 | -54.23 | -1.56K | |
| Normalized Diluted EPS | -0.64 | -31.48 | -33.89 | -976.36 | |
| Average Basic Shares Outstanding | 43.49M | 564.60K | 406.70K | 11.10K | |
| Average Diluted Shares Outstanding | 43.49M | 564.60K | 406.70K | 11.10K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |